News
FDA Approves PrEP Drug Requiring Only Two Injections Per Year
Like other PrEP drugs, if enough of the medication is present when a person is exposed to HIV, it can prevent the virus from taking hold and causing a lifelong infection. Because lenacapavir is long-acting, it requires only two injections per year.
FDA Approves First Twice-a-Year HIV Prevention Shot
Made by Gilead Sciences and sold under the name Yeztugo, the drug gives people a new way to stay protected from HIV without needing daily pills or frequent injections, The New York Times reported. “We’re on the precipice of now being able to deliver the greatest prevention option we’ve had in 44 years of this epidemic,
Leaders of the FDA have published a list of new priorities for the agency. They want to deliver rapidly-approved cures and ...
An FDA pilot program, known as the Commissioner’s Priority Voucher program, could drastically change the way pharmaceutical ...
The FDA is launching a program to reward companies with accelerated drug review and speedy agency feedback, if their actions ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
A federal judge has rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's ...
The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...
WEDNESDAY, June 11, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) says it plans to use artificial ...
A novel weight loss drug in the same class as semaglutide has successfully met its targets in its largest clinical trial yet, ...
The US Food and Drug Administration announced a new national priority voucher plan that aims to cut drug review times to one ...
Food companies are starting to make big changes. The U.S. Food and Drug Administration has proposed a ban on certain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback